KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Notes Payables: 2020-2024

Historic Notes Payables for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Mar 2024 value amounting to $55,000.

  • Recursion Pharmaceuticals' Notes Payables fell 91.68% to $55,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $55,000, marking a year-over-year decrease of 91.68%. This contributed to the annual value of $41,000 for FY2023, which is 57.73% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Notes Payables of $55,000 as of Q1 2024, which was up 34.15% from $41,000 recorded in Q4 2023.
  • In the past 5 years, Recursion Pharmaceuticals' Notes Payables registered a high of $3.1 million during Q2 2021, and its lowest value of $41,000 during Q4 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Notes Payables value was $95,000 (recorded in 2022), while the average stood at $278,333.
  • Its Notes Payables has fluctuated over the past 5 years, first tumbled by 97.03% in 2022, then skyrocketed by 631.58% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Notes Payables (Quarterly) stood at $1.1 million in 2020, then plummeted by 91.61% to $90,000 in 2021, then climbed by 7.78% to $97,000 in 2022, then plummeted by 57.73% to $41,000 in 2023, then tumbled by 91.68% to $55,000 in 2024.
  • Its last three reported values are $55,000 in Q1 2024, $41,000 for Q4 2023, and $695,000 during Q3 2023.